UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of March 2020

 


 

Commission File Number: 001- 39167

 


 

Molecular Data Inc.

 

5/F, Building 12, 1001 North Qinzhou Road, Xuhui District

Shanghai 201109

People’s Republic of China
(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  x          Form 40-F   o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

 

 

 


 

EXHIBIT INDEX

 

Exhibit No.

 

Description

99.1

 

Press Release — Molecular Data Inc. Announces Fourth Quarter and Fiscal Year 2019 Unaudited Financial Results

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

Molecular Data Inc.

 

 

 

 

 

By

:

/s/ Zheng Wang

 

Name

:

Zheng Wang

 

Title

:

Director and Chief Executive Officer

 

Date: March 26, 2020

 

3


Exhibit 99.1

 

Molecular Data Inc. Announces Fourth Quarter and Fiscal Year 2019 Unaudited Financial Results

 

SHANGHAI, March 25, 2020 — Molecular Data Inc. (“Molecular Data” or the “Company”) (Nasdaq: MKD), a leading technology-driven platform in China’s chemical industry, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2019.

 

Fourth Quarter and Fiscal Year 2019 Financial Highlights

 

·                  Net revenues in the fourth quarter of 2019 were RMB4,101.2 million (US$589.1 million), a 38.1% increase from RMB2,969.6 million in the fourth quarter of 2018. Net revenues in fiscal year 2019 were RMB13.2 billion (US$1,902.6 million), a 46.3% increase from RMB9.1 billion in fiscal year 2018.

 

·                  Gross profit in the fourth quarter of 2019 was RMB37.4 million (US$5.4 million), a 10.8% increase from RMB33.7 million in the fourth quarter of 2018. Gross profit in fiscal year 2019 was RMB103.0 million (US$14.8 million), a 28.5% increase from RMB80.2 million in fiscal year 2018.

 

·                  Net loss in the fourth quarter of 2019 was RMB58.1 million (US$8.3 million), compared with RMB166.6 million in the fourth quarter of 2018. Net loss in fiscal year 2019 was RMB191.3 million (US$27.5 million), compared with RMB254.6 million in fiscal year 2018.

 

Fourth Quarter and Fiscal Year 2019 Operational Updates

 

·                  GMV1 under direct sales model in the fourth quarter of 2019 was RMB4,069.9 million, a 37.3% increase from RMB2,964.6 million in the fourth quarter of 2018. GMV under direct sales model in fiscal year 2019 was RMB13.2 billion, a 45.9% increase from RMB9.0 billion in fiscal year 2018.

 

·                  GMV under marketplace model in the fourth quarter of 2019 was RMB65.1 billion, a 63.6% increase from RMB39.8 billion in the fourth quarter of 2018. GMV under marketplace model in fiscal year 2019 was RMB241.9 billion, a 50.5% increase from RMB160.7 billion in fiscal year 2018.

 

·                  Total GMV under direct sales and marketplace models in the fourth quarter of 2019 was RMB69.2 billion (US$9.9 billion), a 61.7% increase from RMB42.8 billion in the fourth quarter of 2018. Total GMV under direct sales and marketplace models in fiscal year 2019 was RMB255.1 billion (US$36.4 billion), a 50.3% increase from RMB169.7 billion in fiscal year 2018.

 

·                  As of December 31, 2019, the Company had accumulated 11,745 customers and 6,253 suppliers on the Company’s online platform under direct sales model, compared with 9,007 customers and 5,163 suppliers as of December 31, 2018.

 

·                  As of December 31, 2019, the Company had accumulated 110,565 customers and 32,836 suppliers on the Company’s online platform under marketplace model, compared with 90,129 customers and 32,011 suppliers as of December 31, 2018.

 


1  “GMV” refers to gross merchandise value of the transaction orders placed by customers under the direct sales model or the gross merchandise value of the transaction orders the Company facilitates between customers and suppliers under the marketplace model during the specified period; under the direct sales model, the GMV does not include discounts or returns by the customers and may include the shipping fees in some cases; under the marketplace model, the GMV does not include shipping fees or discounts, regardless of whether the chemicals are actually delivered or returned.

 

1


 

·                  As of December 31, 2019, the Company had over 229,980 users and accumulated a total number of 116,291 customers and 35,456 suppliers on the Company’s online platform under direct sales and marketplace models, compared with 178,220 users, 94,373 customers and 33,752 suppliers as of December 31, 2018.

 

Management Comments

 

“2019 was a landmark year for us, highlighted by our IPO on the Nasdaq Stock Market, on December 30, 2019, which created immediate and increased brand awareness to new users, customers and partners,” said Dr. Dongliang Chang, Founder of the Company and Chairman of the Board. “We finished 2019 strong with a number of operational and financial achievements across the board. To continue our growth momentum in 2020, our strategies focus on expanding our user base, strengthening customer engagement and retention, as well as further observing and meeting our customers’ evolving and diverse needs along the entire chemical value chain.”

 

“We are pleased to see solid progress with growth across each of our core business segments in 2019. It is worth noting that net revenues from our marketplace model and online membership service both achieved three-digit year-over-year growth,” commented Dr. Zheng Wang, Chief Executive Officer and Director of the Company. “With the increasing need of chemical industry participants to improve their operational efficiencies, the steady growth of the chemical industry, and an increasing internet penetration of the chemical e-commerce market, we believe our comprehensive and sophisticated chemical knowledge engine and business intelligence capabilities, our one-stop comprehensive suite of services, and our innovative big data and AI technologies, place us in an ideal position to further our leadership position in the sector. As we move through 2020, we will continue to invest in our knowledge engine and other technologies while looking forward to further growing our GMV, diversifying our value-added services and expanding global presence.

 

“With respect to the COVID-19 pandemic, since its outbreak, many business operations in China were halted and factories were temporarily closed for a period of time, which would negatively affect our overall financial results in the first quarter of 2020. Depending on the global progression of the outbreak, our ability to obtain chemicals and deliver chemicals to customers may be partly or completely disrupted not only in our Chinese facilities but globally. However, at the same time, we observed increased online traffic on our platform in early 2020 during the outbreak, compared to the same period in 2019, especially from overseas customers and suppliers, which is also in line with our business strategy this year. We are also actively promoting our financial services to customers and suppliers on our platform to address potential financial needs during the outbreak. We believe that we can effectively cope with the dynamics caused by the outbreak and will continue to closely monitor the evolving situation,” Dr. Wang concluded.

 

“We are pleased with our strong financial results for both the fourth quarter and fiscal year 2019, achieving outstanding revenue growth while narrowing net loss. Our balance sheet has also been maintained at a healthy level,” said Mr. Zhaohong Li, Chief Financial Officer of the Company. “With a goal to extend our solid growth trend in 2020, we look forward to further improving our results of operation with an emphasis on margin expansion and operational efficiencies improvement.”

 

2


 

Fourth Quarter 2019 Financial Results

 

Net Revenues

 

Net revenues were RMB4,101.2 million (US$589.1 million), a 38.1% increase from RMB2,969.6 million in the same period of 2018. The increase was primarily attributable to the steady increase in the number of users on the platform.

 

·                  Net revenues from direct sales model were RMB4,079.9 million (US$586.0 million), a 37.6% increase from RMB2,964.6 million in the same period of 2018.

 

·                  Net revenues from marketplace model were RMB15.6 million (US$2.2 million), a 376.9% increase from RMB3.3 million in the same period of 2018.

 

·                  Net revenues from online membership service were RMB3.7 million (US$0.5 million), a 113.2% increase from RMB1.8 million in the same period of 2018.

 

·                  Net revenues from financial service were RMB0.5 million (US$0.07 million), compared with nil in the same period of 2018.

 

Cost of Revenues

 

Cost of revenues was RMB4,063.8 million (US$583.7 million), a 38.4% increase from RMB2,935.9 million in the same period of 2018. This change was primarily due to the increase in net revenues.

 

Gross Profit and Gross Margin

 

Gross profit was RMB37.4 million (US$5.4 million), a 10.8% increase from RMB33.7 million in the same period of 2018. Gross margin decreased to 0.9%, compared with 1.1% in the same period of 2018. The decrease in gross margin was primarily due to a larger amount of basic chemicals that were procured by new users on the platform which have relatively lower gross margin.

 

Operating Expenses

 

Total operating expenses were RMB93.7 million (US$13.5 million), a 52.5% decrease from RMB197.5 million in the same period of 2018. The decrease was primarily due to the reduction of expenses associated with share-based compensation in the fourth quarter of 2019 compared to the same period in 2018.

 

·                  Sales and marketing expenses were RMB25.7 million (US$3.7 million), a 48.9% decrease from RMB50.3 million in the same period of 2018. This was primarily due to decreased share-based compensation for marketing personnel.

 

·                  General and administrative expenses were RMB26.4 million (US$3.8 million), an 80.2% decrease from RMB133.1 million in the same period of 2018. This was primarily due to improved operational efficiencies and decreased share-based compensation for administrative personnel.

 

·                  Research and development expenses were RMB14.5 million (US$2.1 million), a 15.3% decrease from RMB17.2 million in the same period of 2018. This was primarily due to decreased share-based compensation for R&D personnel.

 

3


 

Operating Loss

 

Operating loss was RMB56.4 million (US$8.1 million), compared with RMB163.8 million in the same period of 2018.

 

Net Loss

 

Net loss was RMB58.1 million (US$8.3 million), compared with RMB166.6 million in the same period of 2018.

 

Fiscal Year 2019 Financial Results

 

Net Revenues

 

Net revenues were RMB13.2 billion (US$1,902.6 million), a 46.3% increase from RMB9.1 billion in fiscal year 2018. The increase was primarily attributable to the Company’s efforts to diversify product offerings and an increase in overall GMV.

 

·                  Net revenues from direct sales model were RMB13.2 billion (US$1,897.0 million), a 46.0% increase from RMB9.0 billion in fiscal year 2018. The increase was primarily attributable to an increase in total number of users and customers, an increase in overall GMV, and the expansion of chemical product categories and value-added services.

 

·                  Net revenues from marketplace model were RMB26.5 million (US$3.8 million), a 504.4% increase from RMB4.4 million in fiscal year 2018. The increase was primarily attributable to the increased customer engagement on the platform and the Company’s efforts to provide more value-added services to the customers.

 

·                  Net revenues from online membership service were RMB10.7 million (US$1.5 million), a 211.3% increase from RMB3.4 million in fiscal year 2018. The increase was primarily attributable to the increased number of users signing up for the online membership services.

 

·                  Net revenues from financial service were RMB0.9 million (US$0.1 million), compared with nil in fiscal year 2018, as the Company commenced monetizing on financial service in July 2019.

 

Cost of Revenues

 

Cost of revenues was RMB13.1 billion (US$1,887.8 million), a 46.5% increase from RMB9.0 billion in fiscal year 2018. This change was primarily due to the increase in the purchase volume of chemicals, which was in line with the net revenues growth.

 

Gross Profit and Gross Margin

 

Gross profit was RMB103.0 million (US$14.8 million), a 28.5% increase from RMB80.2 million in fiscal year 2018. Gross margin decreased to 0.8%, compared with 0.9% in fiscal year 2018. The slight decrease in gross margin was primarily due to a larger amount of basic chemicals that were procured by new users on the platform which have relatively lower gross margin.

 

4


 

Operating Expenses

 

Total operating expenses were RMB293.0 million (US$42.1 million), a 7.3% decrease from RMB316.0 million in fiscal year 2018.

 

·                  Sales and marketing expenses were RMB108.9 million (US$15.6 million), a 5.4% increase from RMB103.3 million in fiscal year 2018.

 

·                  General and administrative expenses were RMB104.5 million (US$15.0 million), a 39.9% decrease from RMB173.9 million in fiscal year 2018. This was primarily due to improved operational efficiencies and decreased share-based compensation for administrative personnel.

 

·                  Research and development expenses were RMB45.0 million (US$6.5 million), a 22.1% increase from RMB36.9 million in fiscal year 2018. This was primarily due to the constant increase of R&D investments.

 

Operating Loss

 

Operating loss was RMB190.0 million (US$27.3 million), compared with RMB235.8 million in fiscal year 2018.

 

Net Loss

 

Net loss was RMB191.3 million (US$27.5 million), compared with RMB254.6 million in fiscal year 2018.

 

Certain Balance Sheet Item

 

As of December 31, 2019, the Company had cash, cash equivalents and restricted cash of RMB57.7 million (US$8.3 million), compared to RMB6.5 million as of December 31, 2018.

 

Conference Call

 

The Company’s management will host an earnings conference call at 8:00 PM U.S. Eastern Time on March 25, 2020 (8:00 AM Beijing/Hong Kong time on March 26, 2020).

 

Dial-in details for the earnings conference call are as follows:

 

United States:

 

+1-866-519-4004

International:

 

+65-6713-5090

Hong Kong:

 

800-906-601

Mainland China:

 

400-620-8038

Conference ID:

 

6679446

 

A telephone replay will be available two hours after the call until April 8, 2020 by dialing:

 

United States:

 

+1-855-452-5696

International:

 

+61-2-8199-0299

Replay Access Code:

 

6679446

 

5


 

Additionally, a live and archived webcast of the conference call will be available on the Company’s investor relations website at http://investor.molbase.com/.

 

About Molecular Data Inc.

 

Molecular Data Inc. is a leading technology-driven platform in China’s chemical industry, connecting participants along the chemical value chain through integrated solutions. The Company delivers e-commerce solutions, financial solutions, warehousing and logistics solutions, and SaaS suite that are intended to solve pain points for participants in the traditional chemical industry. Built upon a comprehensive knowledge engine and artificial intelligence (AI) capabilities, the Company’s e-commerce solutions are mainly offered through its online platform, consisting of molbase.com, molbase.cn, Moku Data Weixin account, Chemical Community App and other ancillary platforms.

 

Exchange Rate Information

 

This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB6.9618 to US$1.00, the rate in effect as of December 31, 2019 published by the Federal Reserve Board.

 

Safe Harbor Statement

 

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident,” “potential,” “continue” or other similar expressions. Among other things, the Outlook and quotations from management in this announcement, as well as the Company’s strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a variety of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company’s goals and strategies; the Company’s future business development, results of operations and financial condition; the expected growth of the education market; the Company’s ability to monetize the user base; fluctuations in general economic and business conditions in China; the potential impact of the COVID-19 to the Company’s business operations and the economy in China and elsewhere generally; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and the Company undertakes no duty to update such information, except as required under applicable law.

 

6


 

For investor and media inquiries, please contact:

 

In China:

 

Molecular Data Inc.

Eva Ma

Tel: +86-400-6021-666

E-mail: investor@molbase.com

 

The Piacente Group, Inc.

Emilie Wu

Tel: +86-21-6039-8363

E-mail: molbase@tpg-ir.com

 

In the United States:

 

The Piacente Group, Inc.

Brandi Piacente

Tel: +1-212-481-2050

E-mail: molbase@tpg-ir.com

 

Source: Molbase

 

7


 

MOLECULAR DATA INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands of RMB and US$)

 

 

 

As of December 31,

 

 

 

2018

 

2019

 

 

 

(RMB’000)

 

(RMB’000)

 

(USD’000)

 

 

 

Unaudited

 

Assets

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

Cash and cash equivalents

 

6,477

 

5,156

 

741

 

Restricted cash

 

 

52,518

 

7,544

 

Accounts receivable, net

 

40,730

 

20,424

 

2,934

 

Unbilled receivables

 

12,813

 

106,060

 

15,235

 

Notes receivable

 

2,075

 

124,176

 

17,837

 

Inventories, net

 

7,256

 

4,351

 

625

 

Amounts due from related parties

 

2,366

 

828

 

119

 

Prepayments and other current assets

 

295,985

 

215,125

 

30,900

 

 

 

 

 

 

 

 

 

Total current assets

 

367,702

 

528,638

 

75,935

 

 

 

 

 

 

 

 

 

Non-current assets:

 

 

 

 

 

 

 

Property and equipment, net

 

1,762

 

1,106

 

159

 

Intangible assets, net

 

2,134

 

1,560

 

224

 

Operating lease right-of-use assets

 

 

3,219

 

462

 

 

 

 

 

 

 

 

 

Total non-current assets

 

3,896

 

5,885

 

845

 

 

 

 

 

 

 

 

 

Total assets

 

371,598

 

534,523

 

76,780

 

 

 

 

 

 

 

 

 

Liabilities and Shareholders’ Deficit

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

Short-term borrowings

 

82

 

13,749

 

1,975

 

Accounts payable

 

49,315

 

338,941

 

48,686

 

Deferred revenue

 

153,467

 

107,181

 

15,396

 

Accrued expenses and other liabilities

 

24,709

 

108,034

 

15,518

 

Operating lease liabilities-current

 

 

3,080

 

442

 

Amount due to related parties-current

 

27,844

 

143,958

 

20,678

 

Income taxes payable

 

 

352

 

51

 

 

 

 

 

 

 

 

 

Total current liabilities

 

255,417

 

715,295

 

102,746

 

 

 

 

 

 

 

 

 

Non-current liabilities:

 

 

 

 

 

 

 

Amounts due to related parties-non-current

 

177,776

 

33,453

 

4,805

 

Deferred government grants

 

30

 

 

 

 

 

 

 

 

 

 

 

Total non-current liabilities

 

177,806

 

33,453

 

4,805

 

 

 

 

 

 

 

 

 

Total liabilities

 

433,223

 

748,748

 

107,551

 

 

 

 

 

 

 

 

 

Shareholders’ deficit

 

 

 

 

 

 

 

Ordinary shares

 

98

 

98

 

14

 

Additional paid-in capital

 

498,626

 

537,618

 

77,223

 

Accumulated other comprehensive loss

 

 

(316

)

(45

)

Accumulated deficits

 

(560,349

)

(751,625

)

(107,963

)

 

 

 

 

 

 

 

 

Total shareholders’ deficit

 

(61,625

)

(214,225

)

(30,771

)

 

 

 

 

 

 

 

 

Total liabilities and shareholders’ deficit

 

371,598

 

534,523

 

76,780

 

 

8


 

MOLECULAR DATA INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Amounts in thousands of RMB and US$, except for number of shares and per share data)

 

 

 

Quarter Ended

 

Year Ended

 

 

 

December 31,
2018

 

December 31,
2019

 

December 31,
2019

 

December 31,
2018

 

December 31,
2019

 

December 31,
2019

 

 

 

(RMB’000)

 

(RMB’000)

 

(USD’000)

 

(RMB’000)

 

(RMB’000)

 

(USD’000)

 

 

 

Unaudited

 

Unaudited

 

Total net revenues

 

2,969,580

 

4,101,200

 

589,101

 

9,053,266

 

13,245,839

 

1,902,646

 

Chemical Trading — direct sales model

 

2,964,556

 

4,079,854

 

586,035

 

9,045,458

 

13,206,243

 

1,896,958

 

Chemical Trading — marketplace model

 

3,270

 

15,596

 

2,240

 

4,387

 

26,513

 

3,808

 

Online membership service

 

1,754

 

3,740

 

537

 

3,421

 

10,650

 

1,530

 

Financial service

 

 

494

 

71

 

 

917

 

132

 

Others

 

 

1,516

 

218

 

 

1,516

 

218

 

Cost of revenues

 

(2,935,863

)

(4,063,842

)

(583,734

)

(8,973,097

)

(13,142,828

)

(1,887,849

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

33,717

 

37,358

 

5,367

 

80,169

 

103,011

 

14,797

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing expenses

 

(50,280

)

(25,689

)

(3,690

)

(103,293

)

(108,858

)

(15,636

)

General and administrative expenses

 

(133,079

)

(26,354

)

(3,786

)

(173,872

)

(104,471

)

(15,006

)

Research and development expenses

 

(17,159

)

(14,535

)

(2,088

)

(36,889

)

(45,038

)

(6,469

)

Reversal/(Allowance) for doubtful accounts

 

3,036

 

(27,137

)

(3,898

)

(1,907

)

(34,618

)

(4,973

)

Total operating expenses

 

(197,482

)

(93,715

)

(13,462

)

(315,961

)

(292,985

)

(42,084

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating loss

 

(163,765

)

(56,357

)

(8,095

)

(235,792

)

(189,974

)

(27,287

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expenses, net

 

(3,942

)

(2,193

)

(315

)

(19,049

)

(4,368

)

(627

)

Foreign exchange (loss)/gain

 

(9

)

12

 

2

 

(3,033

)

185

 

27

 

Other income, net

 

838

 

914

 

132

 

3,235

 

3,311

 

475

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss before income tax

 

(166,878

)

(57,624

)

(8,276

)

(254,639

)

(190,846

)

(27,412

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income tax benefits/(expenses)

 

277

 

(430

)

(62

)

 

(430

)

(62

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

(166,601

)

(58,054

)

(8,338

)

(254,639

)

(191,276

)

(27,474

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to Molecular Data Inc.

 

(166,601

)

(58,054

)

(8,338

)

(254,639

)

(191,276

)

(27,474

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

(0.54

)

(0.19

)

(0.03

)

(0.82

)

(0.62

)

(0.09

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

310,627,024

 

310,627,024

 

310,627,024

 

310,627,024

 

310,627,024

 

310,627,024

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other comprehensive income, net of tax of nil

 

 

 

 

 

 

 

Comprehensive loss

 

(166,601

)

(58,054

)

(8,338

)

(254,639

)

(191,276

)

(27,474

)

Comprehensive loss attributable to Molecular Data Inc.

 

(166,601

)

(58,054

)

(8,338

)

(254,639

)

(191,276

)

(27,474

)

 

9